Imbalance between IL-36 receptor agonist and antagonist drives neutrophilic inflammation in COPD
J. R. Baker, P. S. Fenwick, C. K. Coss, H. B. Owles, S. L. Elkin, M. Thomas, J. Fine, K. C. El-Kasmi, P. J. Barnes, L. E. Donnelly
The paper identifies an imbalance between IL-36 receptor agonist and antagonist in COPD patients, showing it drives neutrophilic inflammation and suggests a therapeutic antibody targeting IL-36R as a potential treatment.
bioRxiv · Oct 6, 2021Cell Biology